CellMate is to revolutionize the development of cancer drugs, with the focus on solid tumors. We will address the challenges – high costs, slow pace, and inefficiencies – in drug development. Despite the significant market potential and patients need, the current related preclinical phase struggles with low success rates, largely due to suboptimal testing technologies used in drug discovery process for new drug candidates selection.
CellMate employs cutting-edge technology to develop advanced three-dimensional cell cultures and tailored tissue materials to more accurately mimic tumor tissues. This innovation aims to enhance the drug screening process's efficiency – reducing time and costs in bringing effective treatments to market.
Our project encompasses the key tasks:
- Finalize the development of end user-oriented technology, enabling them to customize and configure the desired test materials fit for individual molecular candidates testing needs.
- Integrate this technology with our innovative materials production, to more accurately replicate tumor tissues.
- Conduct Proof-of-Concept customer studies, to evaluate the potential in supporting cancer drug candidates screening and prepare for commercialization in co-operation with end-users.
The team anticipates a promising commercial outlook for CellMate, planning a staged business expansion aiming for technology sales and use globally. Our team will focus on understanding of related B2B market dynamics and potential risks, tailoring our business model to include extensive market research, IP strategy, and financial feasibility studies.
In summary, CellMate addresses the crucial need in cancer drug development by introducing groundbreaking technologies to significantly improve preclinical drug screening's accuracy and efficiency. This advancement not only promises to reduce the time and costs associated but also accelerates the availability of effective treatments for some of the most challenging cancer forms.
